In addition, in chronic myeloid leukemia (CML) cells, L-asparaginase treatment can inhibit the AKT/mTOR and ERK signaling pathways, contributing to its anti-tumor effect [47]. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.